Totowa

Early diagnosis of cancer improves treatment outcomes, survival rates, and reduces care costs. Monitoring cancer in people at risk is crucial for early detection. The HMH Hennessey Institute for Cancer prevention and Applied Molecular Science HICAP offers clinical cancer screening and risk assessment, along with research on cancer risk and prevention. This study, the CanScan registry, will collect data over time from participants through questionnaires and routine assessments to better understand cancer risk, screening, and diagnostics. Participants will provide data via questionnaires and consent to share information from standard non-research assessments. The registry will gather information on genetic, environmental, and lifestyle factors linked to cancer risk. This observational study does not involve experimental treatments but follows participants to observe cancer-related outcomes and risk factors over time. Participants will be followed for up to 10 years, during which researchers will monitor rates of inherited genetic variants linked to cancer, new cancer cases, genetic risk scores, lifestyle influences, and the impact of early detection on cancer outcomes. Involvement includes completing questionnaires and allowing access to routine clinical data. This long-term observation aims to improve understanding and prevention of cancer in at-risk populations.

Researchers are investigating whether a system using trained detection dogs and artificial intelligence AI can identify breast cancer from a persons breath. The study involves women scheduled for routine breast cancer screenings such as mammograms, ultrasounds, or biopsies. The purpose is to compare the detection results from the dogs and AI to the actual medical screening or biopsy results to evaluate the accuracy of this breath test approach. Participants will provide breath samples by breathing into a surgical mask. These samples will be sent to a specialized laboratory where trained detection dogs and an AI system will analyze the breath for signs of breast cancer. The study includes two groups women scheduled for routine screening and women scheduled for breast biopsy with a higher risk score. The study will run for up to 24 months to assess test performance overall and in various subgroups. During the study, participants will provide breath samples and undergo their scheduled breast cancer screenings or biopsies. Researchers will evaluate the accuracy of the breath test compared to clinical results. Secondary analyses will look at performance in early-stage cancer and the impact of psychological factors. Participants involvement includes providing samples and attending routine screenings, with the total study duration extending up to two years.

Researchers are studying the effects of IMVT-1402 in adults with mild to severe generalized myasthenia gravis, a condition affecting muscle strength. This Phase 3 trial aims to evaluate the efficacy, safety, and tolerability of IMVT-1402 as a treatment option compared to a placebo. The study is randomized and triple-blinded to ensure reliable results. Participants will receive one of two doses of IMVT-1402 or a placebo, all administered by subcutaneous injection once weekly. The treatment periods include an initial 12-week phase, followed by extended dosing periods of 14 weeks and 52 weeks for some groups. The study is designed to assess responses across these timeframes. During the trial, participants will be monitored through various assessments including the MG activities of daily living MG-ADL score and the Quantitative Myasthenia Gravis QMG score. The main outcome focuses on changes in MG-ADL from baseline to week 12. Safety and tolerability will also be tracked throughout the treatment and follow-up periods. The overall participation may last up to several months depending on the treatment group.